Nestlé have published results from a clinical trial evaluating the effect of Reducose® on glucose response following a complete meal. In the study, 30 healthy individuals consumed either 250mg of Reducose® prior to a meal or 250mg Reducose® mixed directly into the meal, with blood glucose measurements recorded every 10 minutes using an Abbott Freestyle Libre continuous glucose monitor (CGM). The results were compared to a control arm that consumed the test meal alone. The study followed a cross-over design, so each subject acted as their own control and participated in all three test groups. This study is the first published clinical trial exploring the effects of Reducose® when taken together with a complete meal (150g rice, 25g white bread, 80g curry sauce, 80g chicken breast) and confirmed the findings of a yet to be published Phynova clinical trial evaluating the effects of Reducose® on glycaemic and insulinaemic responses to a complete meal. The results from the Nestlé study showed significant reduction in the post-prandial glucose (PPG) response to the meal: when taken before the meal, the PPG was lowered by 26% compared with the control arm and lowered by 34% when incorporated directly into the meal. Reducose® also significantly lowered the glucose peak after eating by 28% and 34% respectively. Importantly, Reducose® also optimized the Time-in-Range, the amount of time that the participants blood glucose stayed within optimal blood glucose ranges, with the reported mean glucose values for the Reducose® test groups all being below the recommended maximum postprandial level of 7.8 mmol/L. This study is the first trial to evaluate blood glucose responses using CGMs, highlighting an important benefit of Reducose®: the benefits are immediate and measurable using these new technologies.